ATRA Quote, Financials, Valuation and Earnings

Clearside Biomedical has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of -740.66%. Atara Biotherapeutics's return on equity of -2818.48% beat Clearside Biomedical's return on equity of --.

Atara Biotherapeutics has a consensus price target of --, signalling downside risk potential of -0.18%. On the other hand Clearside Biomedical has an analysts' consensus of -- which suggests that it could grow by 516.78%. Given that Clearside Biomedical has higher upside potential than Atara Biotherapeutics, analysts believe Clearside Biomedical is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.505, which suggesting that the stock is 49.464% less volatile than S&P 500. In comparison Clearside Biomedical has a beta of 2.198, suggesting its more volatile than the S&P 500 by 119.786%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearside Biomedical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Clearside Biomedical pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are larger than Clearside Biomedical quarterly revenues of $1M. Atara Biotherapeutics's net income of -$21.9M is lower than Clearside Biomedical's net income of -$7.7M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Clearside Biomedical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.97x versus 8.90x for Clearside Biomedical. Usually stocks with elevated PS ratios are considered overvalued.

Corvus Pharmaceuticals has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of --. Atara Biotherapeutics's return on equity of -2818.48% beat Corvus Pharmaceuticals's return on equity of --.

Atara Biotherapeutics has a consensus price target of --, signalling downside risk potential of -0.18%. On the other hand Corvus Pharmaceuticals has an analysts' consensus of $14.80 which suggests that it could grow by 161.95%. Given that Corvus Pharmaceuticals has higher upside potential than Atara Biotherapeutics, analysts believe Corvus Pharmaceuticals is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.505, which suggesting that the stock is 49.464% less volatile than S&P 500. In comparison Corvus Pharmaceuticals has a beta of 1.073, suggesting its more volatile than the S&P 500 by 7.259%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Corvus Pharmaceuticals pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are larger than Corvus Pharmaceuticals quarterly revenues of --. Atara Biotherapeutics's net income of -$21.9M is higher than Corvus Pharmaceuticals's net income of -$40.2M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Corvus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.97x versus -- for Corvus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Jaguar Health has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of -317.05%. Atara Biotherapeutics's return on equity of -2818.48% beat Jaguar Health's return on equity of -394.73%.

Atara Biotherapeutics has a consensus price target of --, signalling downside risk potential of -0.18%. On the other hand Jaguar Health has an analysts' consensus of $6.00 which suggests that it could grow by 450.46%. Given that Jaguar Health has higher upside potential than Atara Biotherapeutics, analysts believe Jaguar Health is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.505, which suggesting that the stock is 49.464% less volatile than S&P 500. In comparison Jaguar Health has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.426%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jaguar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Jaguar Health pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are larger than Jaguar Health quarterly revenues of $3.1M. Atara Biotherapeutics's net income of -$21.9M is lower than Jaguar Health's net income of -$9.9M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Jaguar Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.97x versus 0.41x for Jaguar Health. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -54.51% compared to Atara Biotherapeutics's net margin of -108.58%. Atara Biotherapeutics's return on equity of -2818.48% beat SpringWorks Therapeutics's return on equity of -51.38%.

Atara Biotherapeutics has a consensus price target of --, signalling downside risk potential of -0.18%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $67.50 which suggests that it could grow by 66.71%. Given that SpringWorks Therapeutics has higher upside potential than Atara Biotherapeutics, analysts believe SpringWorks Therapeutics is more attractive than Atara Biotherapeutics.

Atara Biotherapeutics has a beta of 0.505, which suggesting that the stock is 49.464% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.943%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $40.2M, which are smaller than SpringWorks Therapeutics quarterly revenues of $49.3M. Atara Biotherapeutics's net income of -$21.9M is higher than SpringWorks Therapeutics's net income of -$53.5M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.97x versus 21.48x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.